A Phase III Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

The primary objective of this study is to evaluate progression-free-survival in patients receiving DCVax-Brain to treat GBM.

Neuroscience - Brain Tumor
Charles Cobbs, MD

Inclusion:

  • 18 to 70 years
  • Life expectancy greater than 8 weeks

Exclusion:

  • History of malignancy
  • History of immuodeficiency or autoimmune disease
Nathan Hansen
206-320-3542